Chemotinib 100mg Capsule (Sunitinib Malate) is a multitargeted receptor tyrosine kinase inhibitor (RTKI) approved for treating renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST), and neuroendocrine tumors. Composition: Each capsule contains 100mg Sunitinib malate base with pharmaceutical excipients. Indications: Sunitinib treats metastatic RCC, GIST resistant to imatinib, advanced pancreatic neuroendocrine tumors (pNET), and thyroid cancer. Clinical efficacy demonstrates improved progression-free survival (11+ months in RCC) versus placebo. Contraindications: Absolute contraindications include hypersensitivity, uncontrolled hypertension, cardiac dysfunction, severe hepatic impairment. Relative caution with cardiac arrhythmias, QTc prolongation baseline, hypertension history. Drug Interactions: Major interactions with CYP3A4 inhibitors (ketoconazole, ritonavir increase levels), CYP3A4 inducers (rifampin reduce levels), QTc-prolonging agents. Dosage & Administration: Standard 50mg daily on 4-weeks-on/2-weeks-off schedule; can reduce to 37.5mg or increase to 62.5mg based on tolerability. Take with/without food; consistent timing preferred. Storage: 15-30°C in original moisture-protective packaging. Side Effects: Common: hypertension (30-50%), fatigue, diarrhea, nausea, mucositis, hand-foot syndrome. Serious: cardiac dysfunction, hepatotoxicity, GI perforation (0.5%), bleeding, thyroid dysfunction. Precautions: Monthly CBC, metabolic panel; baseline and quarterly ECG/MUGA; blood pressure monitoring twice weekly x 2 weeks then monthly; thyroid function baseline and periodically. Pregnancy & Lactation: Sunitinib teratogenic (Category D); absolutely contraindicated in pregnancy. Males require barrier contraception during therapy and 14 days post-treatment. Females require hormonal+barrier contraception with pregnancy testing baseline and monthly. Substitutes & Alternatives: Pazopanib, Axitinib (Inlyta), Sorafenib for RCC; different GIST agents (regorafenib) for imatinib-resistant disease. FAQs: Expected response time 8-12 weeks; hypertension management essential (ACE inhibitor, calcium blocker); cost varies significantly; intermittent schedule improves tolerability. Expected Timeline: Week 4 assessment; Month 2 imaging (CT abdomen/pelvis); Month 3 response confirmation (RECIST); ongoing monthly clinical monitoring. Book Oncology Consultation: Essential for tolerability optimization, cardiac monitoring coordination, hypertension management, and dose modification strategies. Schedule Tests: Baseline CBC, metabolic panel, troponin, TSH; monthly CBC/metabolic panel; baseline and quarterly ECG/ejection fraction measurement; monthly blood pressure; quarterly thyroid function assessment.